Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 2 of 9
Role of the Immune Environment in Response to Therapy in Breast Cancer
NCT05396612
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NCT05427240
SBRT With Atezo/Bev for HCC
NCT05488522
Comparing Two Ways to Manage Head and Neck Lymphedema
NCT05182229
CAR-T Followed by Bispecific Antibodies
NCT04889716
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT04523857
CapTemY90 for Grade 2/3 NET Liver Metastases
NCT04339036
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148
CTNNA1 Familial Expansion Study
NCT05126290
Physiologic MR Imaging of Salivary Gland Tumors
NCT04452162
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
NCT04332367
Autoimmunity After Checkpoint Blockade
NCT04119713
Li-Fraumeni Syndrome/TP53 Biobank
NCT04367246
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
NCT03546829
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT03646617
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
NCT03680677
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT02732171
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
NCT02637934
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT02478892
Ovarian Tissue Transplantation
NCT01870752
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
NCT01985919
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
NCT02346435
The Radiation Oncology Registry and Biosample Repository
NCT01577251
Increasing Screening for Cancer Using EHR-Nudges Replication
NCT06995703
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
NCT06436248
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
NCT06019988
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
NCT06204159
Nudge to Gynecologic Oncology
NCT06451263
A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science Research
NCT05852860
Project Looking-Glass Evaluation
NCT06056063
Penn Medicine Biobank Return of Results Program
NCT06089954
Increasing Adherence to Lung Cancer Screening
NCT05832008
Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening
NCT05693649
The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients
NCT05226078
Shortened Course Adjuvant Radiotherapy Following TORS
NCT05714657
Vaccine Responses in Cancer
NCT06605625
Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care
NCT05331625
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
NCT04827862
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
NCT05338307
XmAb20717 in Advanced Biliary Tract Cancers
NCT05297903
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
NCT05096338
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
NCT05078190
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT04854304
Telehealth Weight Loss Program for Breast Cancer Survivors
NCT04855552
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
NCT04774445
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
NCT04367675
Implementation Strategies for Monitoring Adherence in Real Time
NCT04347161
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT04454528
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
NCT04305613
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets.Report a data error.